Jeffrey Lumerman, MD
Urology · Garden City, NYNPI 1083677272
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.4% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $684 and has fallen 70.1% since, to $205 in 2025. That places this record below the midpoint for urology clinicians in NY, where the typical reported total is $2,467.
Across 88 payments — averaging $25.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$439
- AbbVie$345
- Neotract Inc.$307
- Coloplast$250
- Endo Pharmaceuticals Inc.$110
- Pfizer$88
- plus $674 from 18 others
Across 41 payments — averaging $4982.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$107K
- Urovant Sciences Inc$58K
- Siemens Medical Solutions USA, Inc.$26K
- Sumitomo Pharma America, Inc.$14K
What the payments were for
- Food & beverage$2,11295%
- Education$1015%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 14 | $439 |
| AbbVie | 20 | $345 |
| Neotract Inc. | 5 | $307 |
| Coloplast | 7 | $250 |
| Endo Pharmaceuticals Inc. | 6 | $110 |
| Pfizer | 6 | $88 |
| Civco Medical Instruments | 1 | $83 |
| Blue Earth Diagnostics | 3 | $65 |
| Myriad Genetic Laboratories, Inc. | 3 | $54 |
| Johnson & Johnson | 3 | $50 |
| Astellas Pharma US Inc | 3 | $49 |
| Urovant Sciences Inc | 2 | $44 |
| Progenics Pharmaceuticals, Inc. | 1 | $43 |
| Tolmar Pharmaceuticals, Inc. | 2 | $43 |
| Bayer | 2 | $40 |
| Olympus America Inc. | 2 | $39 |
| Urogen Pharma, Inc. | 1 | $31 |
| Antares Pharma, Inc. | 1 | $25 |
| Merck | 1 | $24 |
| Baudax Bio Inc. | 1 | $22 |
| Hollister Incorporated | 1 | $20 |
| Dentsply IH Inc. | 1 | $18 |
| Axonics, Inc. | 1 | $14 |
| GSK | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$249
- SPEEDICATH$133
How this compares
$2,213 in reported general payments places this provider in the 45th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 172 | $161,923 |
| OrgovyxRelugolix | 11 | $27,969 |
| Silodosin | 229 | $26,010 |
| GemtesaVibegron | 20 | $20,670 |
| Tamsulosin Hcl | 1,112 | $19,555 |
| Finasteride | 1,156 | $16,614 |
| Mirabegron ErMirabegron | 19 | $11,935 |
| Potassium Citrate ErPotassium Citrate | 63 | $7,952 |
| Methenamine Hippurate | 88 | $6,362 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 252 | $5,800 |
| Oxybutynin Chloride ErOxybutynin Chloride | 134 | $3,206 |
| Estradiol | 43 | $3,061 |
| Dutasteride | 68 | $2,686 |
| Solifenacin Succinate | 28 | $1,788 |
| Tolterodine Tartrate ErTolterodine Tartrate | 11 | $997 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $49 | $161,923172 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 952 urology providers in New York.
Other urology in Garden City
- Jeffrey SchiffGarden City$198K
- Shervin BadkhshanGarden City$69K
- Joseph JamalGarden City$53K
- Peter WalterJamestown$1.9M
- Christopher PieczonkaSyracuse$797K
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Jeffrey SpencerCheektowaga$430K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.